glp-1 stomach paralysis law firm in michigan Georgia woman part of lawsuit claiming link between weight loss drugs and blindness – WSB-TV Channel 2 Danish biotech company Zealand Pharma

Accessed March 25, 2026.

On December 22nd, the Food and Drug Administration (FDA) approved Novo Nordisks oral semaglutide tablet, a 25 mg dose of the same active ingredient found in injectable Wegovy and Ozempic

Clinical trials of GLP-1 receptor agonists have shown average reductions in daily energy intake of roughly 2030% during early treatment phases , reflecting the combined effects of increased satiety and reduced food preoccupation

Why Medical Guidance Matters GLP-1 medications are powerful tools, but they are most effective when used under proper medical supervision

Marker Health emphasizes: "Injection site rotation isnt optional nice-to-have advice

If your appetite is not sufficiently suppressed after reaching the target dose, our dedicated medical team will work closely with you to re-evaluate your comprehensive treatment plan and explore alternative medical strategies